Search Results

1-4 of 4 results for subject:Reviews

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health, what the (a) membership and (b) attendance record of each member of the Medicine and Healthcare Products Regulatory Agency selective serotonin reuptake inhibitor review group is. - Inc table and figures.

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

27 January 2005

For answer on

9 March 2005

Answered on

9 March 2005

Mr. Burstow: To ask the Secretary of State for Health what the (a) membership and (b) attendance record of each member of the Medicine and Healthcare Products Regulatory Agency selective serotonin reuptake inhibitor review group is. [213094] Ms Rosie Winterton: The Committee on Safety of Medicines' (CSM) expert working group on the safety of selective serotonin reuptake inhibitors was established in May 2003. The membership included experts in psychiatry, child and adolescent psychiatry/ epidemiology, statistics and general practice, and lay membership. A total of 17 meetings have been held. The membership of the group and the number of meetings each member attended is shown in the table. _________________________________________________________________________________________________. Member Number of meetings attended Professor Ian V. D. Weller (Chair) 116 Professor Deborah Ashby 17 Mr. Richard Brook2 9 Professor Mary G. A. Chambers 7 Dr. Jonathan D. Chick 15 Professor Colin Drummond 8 Professor David J. Gunnell 12 Professor Klaus Ebmeier 16 Ms Hilary Hawking3 3 Dr. Elizabeta Mukaetova-Ladinska 11 Mr. Eamonn O'Tierney4 3 Dr. Ross J. Taylor 14 Dr. Ann York 13 Dr. Morris Zwi 10 _________________________________________________________________________________________________. 1 Professor Gordon Duff, chairman of the CSM, chaired the first meeting of the group. 2 Resigned in March 2004. 3 Appointed in September 2004. 4 Mr. O'Tierney was unable to continue as an active member of the group from July 2003 for personal reasons.

Date

9 March 2005

Reference

431 c1915-6W;431 c1908-9W; 213094

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, how the Medicines and Healthcare Products Regulatory Agency's review of tricyclic drugs will take account of the safety of future classes of anti-depressant drug. - Inc ref to report in Library.

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

23 February 2005

Reference

215711; 431 c679W;431 c675W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, if he will make a statement on the Department's review of patient charges; what the remit of the review is; and when it is expected to report.

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

21 February 2005

Reference

208102; 431 c176W;431 c176-7W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, whether further research recommended by a Health Protection Agency Rapid Review Panel report will be assessed by the panel at a later date; and whether a further report will be issued; how many applications have been reviewed by the Health Protection Agency's...

Asked by

Paul Burstow (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

11 January 2005

Reference

429 c515-6W; 206426;206428;206429;206430

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher